{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:34:55Z","timestamp":1792294495135,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Brazilian National Council for Scientific and Technological Development"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.drudis.2019.05.023","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:23:29Z","timestamp":1559301809000},"page":"1845-1853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?"],"prefix":"10.1016","volume":"24","author":[{"given":"Elaine D.","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael C.","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.05.023_bib0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1574884711666160418105339","article-title":"Endocannabinoid system: a multi-facet therapeutic target","volume":"11","author":"Kaur","year":"2016","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0010","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1476-5381.2011.01497.x","article-title":"Delta(9)-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells","volume":"165","author":"McHugh","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/can.2016.0037","article-title":"Cannabinoid CB1 and CB2 receptor signaling and bias","volume":"2","author":"Ibsen","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2019.05.023_bib0025","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/092986710790980050","article-title":"Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists","volume":"17","author":"Pertwee","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.023_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.plipres.2012.10.001","article-title":"Cannabinoids and omega-3\/6 endocannabinoids as cell death and anticancer modulators","volume":"52","author":"Brown","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brainres.2016.08.037","article-title":"Endocannabinoids in brain plasticity: cortical maturation, HPA axis function and behavior","volume":"1654","author":"Dow-Edwards","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nlm.2016.07.031","article-title":"Endocannabinoid signaling and memory dynamics: a synaptic perspective","volume":"138","author":"Drumond","year":"2017","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.drudis.2019.05.023_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fnins.2017.00293","article-title":"Cannabinoid receptor signaling in central regulation of feeding behavior: a mini-review","volume":"11","author":"Koch","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid rec eptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/chemse\/bjx062","article-title":"Role of endocannabinoids on sweet taste perception, food preference, and obesity-related disorders","volume":"43","author":"Tarragon","year":"2017","journal-title":"Chem. Senses"},{"key":"10.1016\/j.drudis.2019.05.023_bib0060","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2174\/138161208785740090","article-title":"CNS immune surveillance and neuroinflammation: endocannabinoids keep control","volume":"14","author":"Wolf","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.05.023_bib0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-319-20825-1_6","article-title":"Endocannabinoids and the immune system in health and disease","volume":"231","author":"Cabral","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0070","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.2174\/1381612820666140130212957","article-title":"Role of the endocannabinoid system in the neuroendocrine responses to inflammation","volume":"20","author":"De Laurentiis","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.05.023_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1574889810666160517123938","article-title":"Phytocannabinoids and cannabimimetic drugs: recent patents in central nervous system disorders","volume":"10","author":"Ranieri","year":"2016","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.drudis.2019.05.023_bib0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neuroscience.2013.09.005","article-title":"Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis","volume":"254","author":"Ribeiro","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2019.05.023_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1874205X01711010061","article-title":"Do cannabinoids confer neuroprotection against epilepsy? An overview","volume":"11","author":"Capasso","year":"2017","journal-title":"Open Neurol. J."},{"key":"10.1016\/j.drudis.2019.05.023_bib0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nn.3011","article-title":"Moving bliss: a new anandamide transporter","volume":"15","author":"Marsicano","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0095","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.bjp.0705468","article-title":"Cellular accumulation of anandamide: consensus and controversy","volume":"140","author":"Hillard","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0009-3084(00)00191-2","article-title":"The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes","volume":"108","author":"Hillard","year":"2000","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.drudis.2019.05.023_bib0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2017.00921","article-title":"Dual influence of endocannabinoids on long-term potentiation of synaptic transmission","volume":"8","author":"Silva-Cruz","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0110","doi-asserted-by":"crossref","first-page":"33302","DOI":"10.1038\/srep33302","article-title":"Human CB1 receptor isoforms, present in hepatocytes and beta-cells, are involved in regulating metabolism","volume":"6","author":"Gonzalez-Mariscal","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.05.023_bib0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuropharm.2018.03.024","article-title":"Inhibition of mitochondrial permeability transition pore opening contributes to cannabinoid type 1 receptor agonist ACEA-induced neuroprotection","volume":"135","author":"Ma","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.05.023_bib0120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/00207454.2017.1420069","article-title":"Role of the endogenous cannabinoid receptor 1 in brain injury induced by chronic intermittent hypoxia in rats","volume":"128","author":"Gao","year":"2018","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s12640-017-9839-1","article-title":"Cannabinoid receptor type 1 agonist ACEA protects neurons from death and attenuates endoplasmic reticulum stress-related apoptotic pathway signaling","volume":"33","author":"Vrechi","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mcn.2017.07.003","article-title":"Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein","volume":"83","author":"Xu","year":"2017","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12974-018-1072-1","article-title":"Correction to: AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity","volume":"15","author":"Saliba","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.drudis.2019.05.023_bib0140","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.1500546","article-title":"Anandamide suppresses proinflammatory T cell responses in vitro through type-1 cannabinoid receptor-mediated mTOR inhibition in human keratinocytes","volume":"197","author":"Chiurchiu","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5021\/ad.2016.28.1.22","article-title":"Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model","volume":"28","author":"Nam","year":"2016","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0150","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1021\/acs.jmedchem.6b00516","article-title":"Peripherally selective cannabinoid 1 receptor (CB1R) agonists for the treatment of neuropathic pain","volume":"59","author":"Seltzman","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.023_bib0155","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbi.2017.10.021","article-title":"Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization","volume":"68","author":"Braun","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.drudis.2019.05.023_bib0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainres.2017.06.020","article-title":"The synthetic cannabinoid WIN55212-2 ameliorates traumatic spinal cord injury via inhibition of GAPDH\/Siah1 in a CB2-receptor dependent manner","volume":"1671","author":"Su","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/ph10030060","article-title":"Neuroprotective effects of beta-caryophyllene against dopaminergic neuron injury in a murine model of Parkinson\u2019s disease induced by MPTP","volume":"10","author":"Viveros-Paredes","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2019.05.023_bib0175","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11481-017-9744-7","article-title":"Regulation of cell surface CB2 receptor during human B cell activation and differentiation","volume":"12","author":"Castaneda","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0180","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/bph.13215","article-title":"Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia","volume":"173","author":"Garcia","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881110367732","article-title":"Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis","volume":"25","author":"Lanciego","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.05.023_bib0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neulet.2005.11.038","article-title":"Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study","volume":"396","author":"Ashton","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.drudis.2019.05.023_bib0200","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.phrs.2016.07.021","article-title":"Type-2 cannabinoid receptors in neurodegeneration","volume":"111","author":"Bisogno","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FBP.0000000000000337","article-title":"Antinociceptive effects of JWH015 in female and male rats","volume":"29","author":"Craft","year":"2018","journal-title":"Behav Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.05.023_bib0215","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.7717\/peerj.40","article-title":"A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down\u2013regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ","volume":"1","author":"Ramot","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.drudis.2019.05.023_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mehy.2016.12.003","article-title":"Cannabinoids: possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation","volume":"99","author":"Norooznezhad","year":"2017","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.drudis.2019.05.023_bib0225","first-page":"697","article-title":"Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential","volume":"7","author":"Dankers","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0230","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cpt.568","article-title":"Medical cannabis: another piece in the mosaic of autoimmunity?","volume":"101","author":"Katz","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.05.023_bib0235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.autrev.2017.11.019","article-title":"Combined therapies to treat complex diseases: the role of the gut microbiota in multiple sclerosis","volume":"17","author":"Calvo-Barreiro","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.drudis.2019.05.023_bib0240","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40263-017-0466-4","article-title":"Efficacy and tolerability of phytomedicines in multiple sclerosis patients: a review","volume":"31","author":"Farzaei","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2019.05.023_bib0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coi.2017.08.013","article-title":"Immunomodulation in multiple sclerosis: promises and pitfalls","volume":"49","author":"Dendrou","year":"2017","journal-title":"Curr. Opin Immunol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0250","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/jnnp.2007.139071","article-title":"Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis","volume":"79","author":"Di Filippo","year":"2008","journal-title":"J. Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.drudis.2019.05.023_bib0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2009.03.019","article-title":"Endocannabinoids and immune regulation","volume":"60","author":"Pandey","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2019.05.023_bib0265","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1021\/acs.jmedchem.5b01812","article-title":"Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain","volume":"59","author":"Brindisi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.023_bib0270","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neulet.2008.04.090","article-title":"Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis","volume":"439","author":"Webb","year":"2008","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.drudis.2019.05.023_bib0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/glia.22742","article-title":"Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo","volume":"63","author":"Bernal-Chico","year":"2015","journal-title":"Glia"},{"key":"10.1016\/j.drudis.2019.05.023_bib0280","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2015.07.010","article-title":"Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis","volume":"99","author":"Wen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.05.023_bib0285","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1096\/fj.04-2464fje","article-title":"Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis","volume":"19","author":"Ortega-Gutierrez","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2019.05.023_bib0290","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acs.jmedchem.6b00397","article-title":"Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis","volume":"59","author":"Morales","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.023_bib0295","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2016.12.009","article-title":"Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis","volume":"303","author":"Annunziata","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0300","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells","volume":"13","author":"Maresz","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2019.05.023_bib0305","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.neuropharm.2012.01.030","article-title":"Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects","volume":"62","author":"de Lago","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.05.023_bib0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euroneuro.2011.04.004","article-title":"CB1 receptor antagonism\/inverse agonism increases motor system excitability in humans","volume":"22","author":"Oliviero","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1756285615612659","article-title":"Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis","volume":"9","author":"Zettl","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.drudis.2019.05.023_bib0320","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.962","article-title":"The influence of THC: CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity","volume":"8","author":"Celius","year":"2018","journal-title":"Brain Behav."},{"key":"10.1016\/j.drudis.2019.05.023_bib0325","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/802649","article-title":"Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis","volume":"2012","author":"Hilliard","year":"2012","journal-title":"ISRN Neurol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0330","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","article-title":"Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity","volume":"87","author":"Patti","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.drudis.2019.05.023_bib0335","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000445943","article-title":"Influence of previous failed antispasticity therapy on the efficacy and tolerability of THC:CBD oromucosal spray for multiple sclerosis spasticity","volume":"75","author":"Haupts","year":"2016","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0340","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jcph.670","article-title":"Long-term data of efficacy, safety, and tolerability in a real-life setting of THC\/CBD oromucosal spray-treated multiple sclerosis patients","volume":"56","author":"Paolicelli","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0345","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1586\/14737167.2016.1140574","article-title":"A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis","volume":"16","author":"Gras","year":"2016","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0350","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ane.12660","article-title":"Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex((R))","volume":"135","author":"Carotenuto","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.drudis.2019.05.023_bib0355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jns.2017.06.017","article-title":"Sativex(R) effects on promoter methylation and on CNR1\/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients","volume":"379","author":"Santoro","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15026-z","article-title":"Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation","volume":"7","author":"Zgair","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.05.023_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180651","article-title":"Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study)","volume":"12","author":"Messina","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.023_bib0370","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17512433.2017.1292849","article-title":"Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC: CBD oromucosal spray and others?","volume":"10","author":"Maccarrone","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0375","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.drudis.2019.05.023_bib0380","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000442679","article-title":"Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy","volume":"132","author":"Zoja","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.drudis.2019.05.023_bib0385","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drudis.2019.05.023_bib0390","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjmed.2013.03.002","article-title":"The impact of marijuana use on glucose, insulin, and insulin resistance among US adults","volume":"126","author":"Penner","year":"2013","journal-title":"Am. J. Med."},{"key":"10.1016\/j.drudis.2019.05.023_bib0395","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3233\/CH-168021","article-title":"Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes","volume":"64","author":"Lehmann","year":"2016","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.drudis.2019.05.023_bib0400","doi-asserted-by":"crossref","first-page":"E5420","DOI":"10.1073\/pnas.1419901111","article-title":"Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy","volume":"111","author":"Jourdan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.023_bib0405","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gfx010","article-title":"Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy","volume":"32","author":"Barutta","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.drudis.2019.05.023_bib0410","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.bmcl.2014.12.031","article-title":"Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model","volume":"25","author":"Bartolozzi","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2019.05.023_bib0415","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.expneurol.2006.11.013","article-title":"Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats","volume":"204","author":"Duarte","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0420","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2009.04.017","article-title":"Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy","volume":"57","author":"Zhang","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.05.023_bib0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbr.2016.01.027","article-title":"Impaired cued and spatial learning performance and altered cannabinoid CB(1) receptor functionality in the substantia nigra in a rat model of diabetic neuropathy","volume":"303","author":"Moriarty","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.drudis.2019.05.023_bib0430","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc16-0650","article-title":"Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study","volume":"39","author":"Jadoon","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2019.05.023_bib0435","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.drudis.2019.05.023_bib0440","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/03009742.2015.1020863","article-title":"Association between cannabinoid receptor type 2 Q63R variant and oligo\/polyarticular juvenile idiopathic arthritis","volume":"44","author":"Bellini","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0445","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.lfs.2008.09.004","article-title":"Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells","volume":"83","author":"Stebulis","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2019.05.023_bib0450","first-page":"574","article-title":"Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes","volume":"26","author":"Selvi","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.drudis.2019.05.023_bib0455","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","article-title":"Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis","volume":"45","author":"Blake","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.drudis.2019.05.023_bib0460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res. Ther."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:41:00Z","timestamp":1761223260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618304847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1359644618304847"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.023","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}